Pharming Group (NASDAQ:PHAR – Get Rating) – Equities researchers at Oppenheimer raised their FY2026 earnings per share estimates for Pharming Group in a note issued to investors on Thursday, May 12th. Oppenheimer analyst H. Singh now expects that the company will earn $0.06 per share for the year, up from their previous forecast of $0.05.
Separately, Zacks Investment Research lowered Pharming Group from a “hold” rating to a “sell” rating in a report on Tuesday, March 29th.
PHAR stock opened at $8.05 on Monday. The company has a quick ratio of 4.75, a current ratio of 5.33 and a debt-to-equity ratio of 0.72. The business has a 50 day moving average of $8.52 and a 200-day moving average of $8.73. Pharming Group has a 12-month low of $6.71 and a 12-month high of $12.56.
Pharming Group (NASDAQ:PHAR – Get Rating) last issued its quarterly earnings data on Thursday, March 17th. The company reported $0.01 EPS for the quarter, hitting analysts’ consensus estimates of $0.01. The company had revenue of $52.77 million for the quarter, compared to the consensus estimate of $57.59 million.
Several hedge funds have recently added to or reduced their stakes in the company. Cowen Prime Advisors LLC lifted its stake in Pharming Group by 134.9% in the fourth quarter. Cowen Prime Advisors LLC now owns 14,800 shares of the company’s stock valued at $132,000 after purchasing an additional 8,500 shares during the last quarter. Jane Street Group LLC lifted its stake in Pharming Group by 37.6% in the third quarter. Jane Street Group LLC now owns 17,441 shares of the company’s stock valued at $164,000 after purchasing an additional 4,767 shares during the last quarter. Finally, Morgan Stanley lifted its stake in Pharming Group by 5,208.3% in the second quarter. Morgan Stanley now owns 2,548 shares of the company’s stock valued at $29,000 after purchasing an additional 2,500 shares during the last quarter. 0.03% of the stock is owned by institutional investors.
About Pharming Group (Get Rating)
Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company’s lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema.
Receive News & Ratings for Pharming Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pharming Group and related companies with MarketBeat.com’s FREE daily email newsletter.